Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial

IMPORTANCE: Taxanes with trastuzumab and pertuzumab for initial treatment of human epidermal growth factor receptor 2 (ERBB2, formerly HER2)–positive metastatic breast cancer is associated with improved progression-free survival (PFS) and overall survival. While continued use of trastuzumab in thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyengar, Neil M., Smyth, Lillian M., Lake, Diana, Gucalp, Ayca, Singh, Jasmeet C., Traina, Tiffany A., DeFusco, Patricia, Fornier, Monica N., Goldfarb, Shari, Jhaveri, Komal, Modi, Shanu, Troso-Sandoval, Tiffany, Patil, Sujata, Ulaner, Gary A., Jochelson, Maxine, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902832/
https://www.ncbi.nlm.nih.gov/pubmed/31774522
http://dx.doi.org/10.1001/jamanetworkopen.2019.16211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902832/
https://www.ncbi.nlm.nih.gov/pubmed/31774522
http://dx.doi.org/10.1001/jamanetworkopen.2019.16211

Ejemplares similares